Response patterns with combination IDH inhibitor + induction chemotherapy. (A) Bar graph showing numbers and percentages of patients receiving the IDH1 inhibitor ivosidenib (IDH1i) or the IDH2 inhibitor enasidenib (IDH2i) with each morphologic response pattern. (B) Box-and-whisker charts showing day 14 BM cellularity and day 14 BM blast percentage for patients with each morphologic response pattern.